Jagsonpal Pharmaceuticals Limited — Investor Meet, 21-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Jagsonpal Pharma reported stable Q3FY26 results: Revenue at ₹72.9 Cr (-1% YoY), Operating EBITDA ₹16.6 Cr (-3% YoY), and PAT ₹12.5 Cr (+10% YoY), with margins at 17.1%. For 9MFY26, Revenue grew 6% YoY to ₹223 Cr, Operating EBITDA rose 5% to ₹50.3 Cr, and PAT increased 13% to ₹35.9 Cr. The company boasts a robust cash balance of ₹175.7 Cr. Management highlighted ongoing growth initiatives and expects stronger Q4 performance, driven by new product launches and strategic acquisitions, reinforcing an asset-light model and strong market position.